



Endless Biotech

Cultivating the Future of Agriculture

Forward-Looking Statements

These offering materials may contain forward-looking statements and information relating to, among other things, the company, its business plan and strategy, and its industry. These forward-looking statements are based on the beliefs of, assumptions made by, and information currently available to the company's management. When used in the offering materials, the words "estimate," "project," "believe," "anticipate," "intend," "expect" and similar expressions are intended to identify forward-looking statements. These statements reflect management's current views with respect to future events and are subject to risks and uncertainties that could cause the company's actual results to differ materially from those contained in the forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made. The company does not undertake any obligation to revise or update these forward-looking statements to reflect events or circumstances after such date or to reflect the occurrence of unanticipated events.

Please note investors in this offering will be clients of the issuer and not Dalmore Group, LLC ("Dalmore"), a registered broker-dealer and member FINRA/SIPC. Dalmore's role in the transaction is to facilitate back-office and regulatory functions related to the Regulation A transaction, and acts only as the broker/dealer of record for the offering listed. Dalmore is not providing investment advice or recommendations, or legal or tax advice.

This Reg A investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. All investors should make their own determination, with the assistance of their own financial or other advisors, as to whether or not to make any investment, based on their own independent evaluation, analysis, and circumstances.

No money or other consideration is being solicited, and if sent in response, will not be accepted. No offer to buy the securities can be accepted and no part of the purchase price can be received until the offering statement filed by the company with the SEC has been qualified by the SEC. Any such offer may be withdrawn or revoked, without obligation or commitment of any kind, at any time before notice of acceptance given after the date of qualification. An indication of interest involves no obligation or commitment of any kind. An offering statement regarding this offering has been filed with the SEC. You may obtain a copy of the preliminary offering circular that is part of that offering statement. [\[Form 1-A filing with SEC\]](#)


Industry Problem

Inconsistency, contamination, scalability, and preservation issues limit growth



INCONSISTENT
QUALITY

Traditional methods produce variable plants, risking product reliability.




DISEASE AND
PEST RISKS

Contamination reduces yields and drives up costs.



LIMITED
SCALABILITY

Current propagation techniques can't keep pace with market demands.




GENETIC
VULNERABILITY

Rare strains are lost due to outdated preservation.

Solution

Precision, preservation, data, and scalability redefine cannabis cultivation




TISSUE CULTURE
TECHNOLOGY

Produces consistent, disease-free plants at scale with unmatched precision.




PRESERVING
GENETICS

Protects rare and valuable strains through cutting-edge preservation techniques.



DATA-DRIVEN
INNOVATION

Utilizes robotics, AI, and molecular diagnostics for optimized growth processes.



SCALABLE
PRODUCTION

Delivers millions of identical, high-quality clones reliably and efficiently.

Tissue Culture Technology

Revolutionizing Cannabis Cultivation Through Tissue Culture


At Endless Biotech, precision isn't a goal—it's the standard. Tissue culture has transformed how cannabis is cultivated, ensuring every plant thrives with unparalleled consistency and care.

Tissue culture isn't just about growing plants—it's about cultivating innovation, sustainability, and the future of agriculture.




HEALTHIER PLANTS

Disease and pest-free plants ensure robust, thriving crops.




CONSISTENT QUALITY

Plants are engineered as identical clones, ensuring consistent potency and quality.



ACCELERATED GROWTH

Faster-growing plants lead to quicker harvests and higher efficiency.



EFFICIENT SPACE USE


Efficient production maximizes space while reducing costs.

Genetic Preservation

Safeguarding the Legacy of Cannabis Cultivation

Preserving cannabis genetics is no longer a challenge—it’s an opportunity. At Endless Biotech, we ensure that cultivators never lose the unique traits that define their success.

Endless Biotech’s genetic preservation secures the legacy of cannabis cultivation, paving the way for innovation and excellence for generations to come.



COMPREHENSIVE STRAIN LIBRARY

Ensures consistency with a reliable source of genetics.




ADVANCED TISSUE CULTURE TECHNIQUES

Preserves purity and original traits in a sterile environment.



LONG-TERM VIABILITY

Secures stability for future cultivation and breeding.



PATHOGEN-FREE PRESERVATION


Eliminates disease and pests for healthier plants.

Data-Driven Innovation

Smart Cultivation Through Data


Our data-driven approach transforms every stage of the process, from predicting growth patterns to optimizing plant health and yield. With advanced robotics and adaptive AI, Endless Biotech leads the charge in precision cultivation.

Endless Biotech’s innovation paves the way for an automated, scalable future where cutting-edge technology meets sustainable growth—ensuring unmatched success for our partners.



AI-POWERED
PRECISION

Adaptive AI ensures consistent, optimal results across cultivation cycles.



ROBOTICS
INTEGRATION

Advanced robotics streamline labor-intensive tasks for greater efficiency.



PREDICTIVE
ANALYTICS


Insights forecast growth patterns and optimize plant health and yields.



ENHANCED
SCALABILITY

Automated systems enable rapid growth without compromising quality.

Endless Biotech’s Scalability Breakthrough



million
identical
plants...

Endless Biotech is building toward the ability to scale from a single tissue culture to over 7 million identical plants **within 120 days.**

...and we
can do this
for every
single
customer!

Expanding our Verticals

While Endless Biotech’s tissue culture expertise currently powers cannabis cultivation at scale, we are actively researching and developing cutting-edge solutions for a broader agricultural future. Our meticulous approach to plant genetics transcends the cannabis sector, focusing on four key areas:




HORTICULTURE

Advanced horticultural genetics ensuring improved yield, resilience, and consistency.



TREE SPECIES

Reliable, genetically optimized tree varieties for sustainable landscaping and agricultural applications.



FLORICULTURE

Specialized floriculture genetics for vibrant and resilient blooms.



CANNABIS

Meticulously cultivated cannabis genetics engineered for optimal growth and unmatched potency.

Expanding Beyond Cannabis

Research & Development: Stage 3

Horticulture

Advanced horticultural genetics aimed at improving yield, resilience, and consistency in everyday staple crops.

Future-forward R&D to enhance the reliability of produce for growers worldwide.

Fruits/Berries

- Strawberry
- Banana
- Blueberry
- Fig

Vegetables/Edibles

- Potato
- Sweet Potato
- Corn



Expanding Beyond Cannabis


Research & Development: Stage 2

Tree Species

Reliable, genetically curated tree varieties for sustainable landscaping and large-scale agricultural applications.

Early-stage research targeting higher survival rates and uniform growth patterns in commercial forestry.

- Paulownia (Empress tree)
- Ficus



Expanding Beyond Cannabis

|||| Research & Development: Stage 1

Floriculture

Specialized genetics for vibrant, resilient blooms, including refined Orchids and robust Chrysanthemums.

Leveraging tissue culture to unlock unique ornamental plant varieties for florists and horticultural enthusiasts.

- Mums
- Carnation
- Gerbera
- Orchids



Currently in full-scale production

|||| In Production

Cannabis

Currently in full-scale production with cultivated Indica, Sativa, and Hybrid varieties—engineered for optimal growth and improved output.

Continual refinement of tissue culture protocols to maintain consistency and maximize yields.

- Indica
- Sativa
- Hybrid



Where We Are Today

Cannabis is our fully operational initial production sector, generating revenue and showing efficacy of our tissue culture model at a commercial scale.

Horticulture, Trees, and **Floriculture** remain in R&D, leveraging the same high-precision tissue culture techniques to pave the way for future expansions into global agriculture.

Why It Matters

By diversifying our research and capabilities, Endless Biotech aims to position itself as a leading biotech innovator, not just in cannabis but in agriculture at large.

This multi-pronged approach safeguards us against market fluctuations in any one sector and sets the stage for significant long-term growth.

Market Opportunity

A Booming
Global
Cannabis
Market

228_M

**Cannabis consumers worldwide.

76₊

***Countries have legalized
some form of medical
cannabis.

\$444_B

*Projected global market size by 2030.

CAGR 34%

*Compound annual growth rate through 2030.

Key Performance Indicators

Endless
Biotech
by the
Numbers

\$2.2_M

Traditional clones revenue.

\$20_M

Turned away in orders.

230_k





Clones sold in a small Oklahoma market.

\$120_M

Global leads and counting.

Scaling for the Future

4 Phases of Growth



PHASE I: PROOF OF CONCEPT

Status

Complete

Objective

Validate cloning feasibility for the cannabis industry.

Outcome

Established high-quality clone production and market demand.

PHASE II: INITIAL EXPANSION

Status

Complete

Objective

Remodel Building I for 40,000+ clones/month.

Outcome

Optimized space, workflows, and production capacity.

PHASE III: SCALING UP

Status

In Progress

Objective

Expand Building I to scale capacity to ±1M clones/month.

Outcome

Architectural plans and permitting in progress.

PHASE IV: GLOBAL GROWTH

Status

Planned

Objective

Construct 40k sq. ft. Building II for 5M clones/month.

Outcome

State-of-the-art facilities for global distribution & efficiency.



Phase I: Proof of Concept

**Established high-quality
clone production and
market demand.**

✓ Complete

6-24



Phase II: Initial Expansion

**Optimized space,
workflows, and
production capacity.**


 Complete

Phase III: Scaling Up

Expand Building I to scale capacity to $\pm 1\text{M}$ clones/month.



In Progress





Phase IV: Global Growth

Building the foundation for global scalability and precision.

The 40,000 sq. ft. facility will increase capacity to over 5M clones/month, featuring cutting-edge labs and climate-controlled systems.

Integrating robotics and AI to streamline production, enhance precision, and cut costs while ensuring consistent quality.

The full campus will drive international expansion, positioning Endless Biotech as a leader in scalable agriculture.

Phase III: Scaling Up – Completed (Q4 2025)


Revenue Potential



Disclaimer: This figure represents a targeted projection based on internal estimates. Actual results may vary, and there is no guarantee the company will reach this level of revenue or clone production capacity.

Phase IV: Global Growth – Completed

Revenue Potential




Disclaimer: This figure represents a targeted projection based on internal estimates. Actual results may vary, and there is no guarantee the company will reach this level of revenue or clone production capacity.

Revenue Strategy Overview

Innovating Growth Across Multiple Verticals

Scaling Across High-Growth Verticals

Our revenue strategy spans five distinct verticals—each targeting high-growth markets with scalable, tech-enabled solutions.




CANNABIS

Precision-grown plants via tissue culture and robotics.



HEMP

High-yield genetics for textiles, fuel, and construction.



ORNAMENTALS

Disease-free decorative plants, scaled through tissue culture.



AGRICULTURE

Boosting soybean & wheat germination across Indian farmland.



EDUCATION

Turning our biotech IP into scalable online learning platform.

Tissue Culture at Scale

Cannabis

This vertical centers on cannabis tissue culture and proprietary genetic development—engineered for precision, consistency, and high-performance yield. With full-scale operations underway, Endless is leveraging biotech to meet rising demand across both medical and adult-use markets.

Endless is redefining scalable cannabis cultivation through disease-free, uniform genetics and closed-loop propagation systems built for global expansion.

- Advanced tissue culture protocols
- AI/ML for environmental control & optimization
- Robotic automation in propagation and harvesting



- EBITDA margin: 25%
- OpEx = 55% of Revenue
- Headcount CAGR: +20% YoY

Revenue
\$60M

EBITDA
\$15M

OpEx
\$33M

Year 1
95 people

Revenue
\$75M

EBITDA
\$18.75M

OpEx
\$41.25M

Year 2
140 people

Revenue
\$93.75M

EBITDA
\$23.4M

OpEx
\$51.6M

Year 3
187 people


Genetic Innovation for Industrial Agriculture

Industrial Hemp

This vertical is focused on industrial-scale agriculture, with Endless developing high-yield, resilient hemp genetics tailored for mass adoption across textiles, construction, and sustainable consumer goods. By applying biotech precision to hemp—a notoriously inconsistent crop—Endless aims to bring stability and scalability to the broader Big Ag supply chain.

The company’s strategy is to become the primary supplier of elite hemp genetics for large-scale growers and processors, replacing traditional seed stock with clean, replicable, performance-optimized cultivars.

- Proprietary high-yield industrial hemp genetics
- Engineered for large-scale cultivation and processing
- Designed for high-performance across multiple industrial applications



- EBITDA margin: 25%
- OpEx = 50% of Revenue
- Headcount CAGR: +20% YoY

Revenue
\$150M

EBITDA

\$37.5M

OpEx

\$75M

Year 1

 30 people

Revenue
\$187.5M

EBITDA

\$46.88M

OpEx

\$93.75M

Year 2

 36 people

Revenue
\$234.4M

EBITDA

\$58.6M

OpEx

\$117.2M

Year 3

 43 people

Consistent Beauty at Commercial Scale

Ornamentals

This vertical targets the high-margin, high-volume world of decorative plant production. Endless applies tissue culture to deliver uniform, disease-free ornamentals at scale—solving the inconsistency, fragility, and inefficiency that have long plagued commercial nurseries and distributors.

By providing predictable, contract-grown ornamentals, Endless helps distributors minimize shrink, improve delivery timelines, and meet demand with absolute consistency—something traditional seed-based production struggles to achieve.

- Tissue culture propagation for large-scale ornamental production
- Uniform, disease-free plant output with high germination success
- Scalable contracts for nurseries and regional distributors



\$1.1B 2%

\$2.2B 4%

\$3.8B 7%

Target Capture

Ornamentals is slated for Year 4 launch, leveraging infrastructure and learnings from our Cannabis and Hemp scale-up. This Phase II vertical taps into a \$127B ornamental plant market with biotech-enabled consistency.

Revenue
N/A

Revenue
N/A

Revenue
N/A

Year 1

Year 2

Year 3

Year 4


Seed Innovation for a Growing Nation

India Germination

This vertical targets India’s vast soybean and wheat markets, where low germination rates and unreliable seed stock create persistent inefficiencies. Endless is partnering with agricultural stakeholders to introduce biotech-enhanced seeds and tissue culture techniques designed to dramatically increase yield, consistency, and resilience in Indian climates.

By deploying optimized seed genetics and scalable propagation systems, Endless aims to modernize India’s seed infrastructure—starting with two of the country’s most critical staple crops.

- Biotech-augmented seed protocols for soybean and wheat
- Strategic entry into India’s agri-modernization efforts
- Designed to boost germination success and yield at scale



- EBITDA margin: 25%
- OpEx = 45% of Revenue
- Headcount CAGR: +20% YoY

Revenue
\$300M

EBITDA
\$75M

OpEx
\$135M

Year 1

40 people

Revenue
\$375M

EBITDA
\$93.75M

OpEx
\$168.75M

Year 2

48 people

Revenue
\$468.75M

EBITDA
\$117.2M

OpEx
\$210.94M

Year 3

57 people


Turning Expertise Into Scalable Education

Education




The Education vertical transforms Endless’ proprietary knowledge, systems, and biotech insights into a digital platform built for growers, lab operators, and industry professionals. From genetics to germination, the platform offers modular learning designed to elevate skill, standardize practices, and accelerate global adoption of precision cultivation.

Unlike infrastructure-heavy verticals, Education scales without physical barriers. It’s built to deliver global reach with minimal overhead—creating a high-margin, always-on channel for monetizing Endless’ intellectual capital.

- Modular education platform for biotech cultivation and propagation
- Targeted content for growers, labs, and operational leads
- Built to scale globally with low overhead, high margin, and recurring revenue



- EBITDA margin: 25%
- OpEx = 60% of Revenue
- Headcount CAGR: +20% YoY



Vertical	Addressable TAM	Growth TAM	Target Growth Capture	Projected Revenue
Cannabis ¹	\$174B	\$65B	2%	~\$1.3B
Industrial Hemp ²	\$48B	\$10B	2%	~\$200M
Ornamentals ³	\$127B	\$54B	2%	~\$1.1B
India Germination ⁴	–	\$30B+	1%	~\$300M
Education ⁵	\$46B	\$4B	5%	~\$200M

¹ [New Frontier Data](#), [BDSA](#), [Statista](#), and [Grand View Research](#)

² [Markets and Markets](#), [Brightfield Group](#), and [USDA projections](#)

³ [IBIS World](#), [USDA Floriculture Reports](#), and [Statista](#)

⁴ [USDA Foreign Ag Service](#), [India's Ministry of Agriculture](#), [IMARC](#), and [McKinsey India Agri Reports](#)

⁵ [HolonIQ](#), [Global Market Insights](#), and [EdTech Market Reports](#)



- Average EBITDA Margin: 25%
- Average OpEx: ~49% of Revenue
- Average Headcount CAGR: ~+20% YoY

Revenue
\$558M

EBITDA

\$139.5M

OpEx

\$271.8M

Year 1

 180 people

Revenue
\$697.5M

EBITDA

\$174.4M

OpEx

\$339.8M

Year 2

 242 people

Revenue
\$871.9M

EBITDA

\$223.4M

OpEx

\$424.7M

Year 3

 308 people

Trusted by Industry Leaders

“

Endless Biotech’s facility is top-notch and impeccably clean. Their passionate and professional team operates with cutting-edge efficiency, delivering exceptional, science-backed, data-driven results. If you’re looking for the future of cannabis cultivation, Endless is the answer.

John Pratt, Regional Sales, Quest

“

Endless Biotech is redefining Crop Steering Methodology with phenomenal yields and unmatched product quality. They’re making waves locally, nationally, and internationally—watching their growth in the coming years will be exciting!

Andrew Tharp, Regional Sales, Grodan

“

Endless Biotech has transformed Tulsa into a hub for cutting-edge cannabis cultivation. With a state-of-the-art facility and a team driven by science and passion, they’re setting new industry standards for clean, high-quality genetics. A force to watch in the cannabis industry!

Mike Howard, Chief Horticulture Officer, FoHSE



Meet the Team

TRAVIS
DAHM

Chief Executive Officer



Driving visionary leadership with a focus on scalability and innovation in agriculture.

BRAZ
VAIDYA

Chief Scientist



Spearheading tissue culture advancements with 15+ years of research experience.

GARY
HOLLAND

Chief Innovation Officer



Combining engineering expertise and AI innovation to optimize operations and drive scalable solutions.

COURTNEY
BRIDGES

Head of Analytics




Blending biology and data science to ensure optimal plant health and operational efficiency.

Funding Breakdown

Capital Allocation Overview

To meet the growing global demand for scalable, precision-grown plant systems, Endless Biotech is allocating \$15 million across five strategic categories.

This funding will support infrastructure expansion, innovation, acquisitions, and operational excellence—positioning Endless as a global leader in tissue culture and biotech propagation.



Join the Future of Agriculture

Your investment empowers us to complete key phases in our growth strategy, paving the way for our planned Nasdaq listing by 2028.

- ✓ Targeted Laboratory Expansion
- ✓ Develop Operations
- ✓ Scale Production Capacity
- ✓ Strategic Hires

In no way limiting the forgoing, any reference to any objective, goal, intention, or plan of Endless Corporation becoming, emulating, or operating in a similar manner as Fortune 100 and 500 companies is not a guarantee that it will be able to do so, or will not elect to do otherwise, now or in the future. In addition, while this website may reference aspirations of Endless Corporation for a NASDAQ IPO, it is still formulating and has not yet decided on or yet implemented a plan to achieve such result. Future results are not guaranteed, nor is how, the capability to achieve such results, and no investment decision should be based upon the potential of a future NASDAQ IPO, or any other potential future event discussed herein.

Visit: investendless.com